论文部分内容阅读
目的:研究分析恶性肿瘤患者凝血功能检测指标,探讨其对于该疾病临床治疗的作用。方法:选取2010年4月至2014年4月入住本院接受磁珠凝固法检测的22例恶性肿瘤患者作为试验组,另外选择同期17例健康体检人员作为对照组,对两组患者的各项凝血指标进行检测,探讨两组凝血指标差异。结果:试验组患者纤维蛋白原出现明显增高,与对照组人员相比存在明显差异,具有统计学意义(P<0.0.5);两组患者血浆凝血酶原时间、部分凝血活酶时间以及凝血酶时间指标比较不存在明显差异,不具有统计学意义(P<0.05)。结论:针对纤维蛋白原实施临床监测有利于促进恶性肿瘤患者临床治疗工作的顺利开展,有效预防恶性肿瘤患者发生高凝现象,改善其预后性,具有良好的应用价值。
Objective: To study the index of coagulation test in patients with malignant tumor and to explore its effect on the clinical treatment of this disease. Methods: Twenty-two patients with malignant tumor admitted to our hospital from April 2010 to April 2014 undergoing magnetic bead coagulation test were selected as the experimental group. In the same period, 17 healthy people were selected as the control group, Coagulation index test to explore differences in coagulation index between the two groups. Results: The fibrinogen in the experimental group was significantly higher than that in the control group (P <0.0.5). The plasma prothrombin time, partial thromboplastin time and blood coagulation There was no significant difference in enzyme time index, which was not statistically significant (P <0.05). Conclusion: The clinical monitoring of fibrinogen is conducive to the promotion of clinical treatment of malignant tumor patients carried out smoothly, effectively prevent the occurrence of hypercoagulability in patients with malignant tumors to improve its prognosis, and has good value.